2017
DOI: 10.1186/s12885-017-3844-x
|View full text |Cite
|
Sign up to set email alerts
|

High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study

Abstract: BackgroundFor metastatic spinal cord compression (MSCC), conventional radiotherapy with 10 × 3 Gy in 2 weeks results in better local progression-free survival (LPFS) than 5 × 4 Gy in 1 week. Since patients with MSCC are often significantly impaired, an overall treatment time of 1 week would be preferable if resulting in similar outcomes as longer programs. This may be achieved with 5 × 5 Gy in 1 week, since the biologically effective dose is similar to 10 × 3 Gy. It can be expected that 5 × 5 Gy (like 10 × 3) … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
12
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(13 citation statements)
references
References 20 publications
0
12
0
Order By: Relevance
“…Propensity score techniques will be applied to reduce confounding due to differences between the historical control group and prospective trial data [14]. The inclusion and exclusion criteria are almost identical to those of a previous trial investigating 5x5Gy of precision radiotherapy of MSCC [11]. Only the inclusion criteria are supplemented by favorable survival prognosis (defined as 36–45 points on a survival score) [1, 2].…”
Section: Methodsmentioning
confidence: 99%
See 4 more Smart Citations
“…Propensity score techniques will be applied to reduce confounding due to differences between the historical control group and prospective trial data [14]. The inclusion and exclusion criteria are almost identical to those of a previous trial investigating 5x5Gy of precision radiotherapy of MSCC [11]. Only the inclusion criteria are supplemented by favorable survival prognosis (defined as 36–45 points on a survival score) [1, 2].…”
Section: Methodsmentioning
confidence: 99%
“…This maximum dose is estimated to be associated with a risk of radiation-related myelopathy of < 0.2% [9]. Both the EQD2 of the prescribed dose (45.1Gy) and the EQD2 of the maximum dose (46.1Gy, α/β = 2.5Gy) are below the tolerance dose of bone of 52Gy [9, 11]. The mean doses (EQD2) for esophagus, heart and lung must be <34Gy, <26Gy and ≤ 7Gy [9].…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations